JP7531707B2 - 癌を処置するためのパラアミノ馬尿酸(pah)および放射能標識された複合体の組合せ - Google Patents

癌を処置するためのパラアミノ馬尿酸(pah)および放射能標識された複合体の組合せ Download PDF

Info

Publication number
JP7531707B2
JP7531707B2 JP2023527358A JP2023527358A JP7531707B2 JP 7531707 B2 JP7531707 B2 JP 7531707B2 JP 2023527358 A JP2023527358 A JP 2023527358A JP 2023527358 A JP2023527358 A JP 2023527358A JP 7531707 B2 JP7531707 B2 JP 7531707B2
Authority
JP
Japan
Prior art keywords
pah
cancer
salt
radiolabeled
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023527358A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023547689A5 (cg-RX-API-DMAC7.html
JP2023547689A (ja
Inventor
メッケル,マリアン
オスル,テレーザ
チェルノセコフ,コンスタンティーン
Original Assignee
アイティーエム アイソトープ テクノロジーズ ミューニック エスイー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイティーエム アイソトープ テクノロジーズ ミューニック エスイー filed Critical アイティーエム アイソトープ テクノロジーズ ミューニック エスイー
Publication of JP2023547689A publication Critical patent/JP2023547689A/ja
Publication of JP2023547689A5 publication Critical patent/JP2023547689A5/ja
Application granted granted Critical
Publication of JP7531707B2 publication Critical patent/JP7531707B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023527358A 2020-11-05 2021-11-05 癌を処置するためのパラアミノ馬尿酸(pah)および放射能標識された複合体の組合せ Active JP7531707B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2020/081143 2020-11-05
PCT/EP2020/081143 WO2022096103A1 (en) 2020-11-05 2020-11-05 Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
PCT/EP2021/080822 WO2022096673A1 (en) 2020-11-05 2021-11-05 Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer

Publications (3)

Publication Number Publication Date
JP2023547689A JP2023547689A (ja) 2023-11-13
JP2023547689A5 JP2023547689A5 (cg-RX-API-DMAC7.html) 2023-11-20
JP7531707B2 true JP7531707B2 (ja) 2024-08-09

Family

ID=73138835

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023527358A Active JP7531707B2 (ja) 2020-11-05 2021-11-05 癌を処置するためのパラアミノ馬尿酸(pah)および放射能標識された複合体の組合せ

Country Status (13)

Country Link
US (1) US20230414796A1 (cg-RX-API-DMAC7.html)
EP (1) EP4065176B1 (cg-RX-API-DMAC7.html)
JP (1) JP7531707B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230127212A (cg-RX-API-DMAC7.html)
CN (1) CN116981487A (cg-RX-API-DMAC7.html)
AU (1) AU2021375728A1 (cg-RX-API-DMAC7.html)
DK (1) DK4065176T3 (cg-RX-API-DMAC7.html)
ES (1) ES2967379T3 (cg-RX-API-DMAC7.html)
FI (1) FI4065176T3 (cg-RX-API-DMAC7.html)
HU (1) HUE065304T2 (cg-RX-API-DMAC7.html)
PL (1) PL4065176T3 (cg-RX-API-DMAC7.html)
WO (2) WO2022096103A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202304769B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR2022007815A1 (tr) * 2022-05-13 2023-11-21 Ege Ueniversitesi Idari Ve Mali Islerdaire Bsk Yüksek stabi̇li̇teye ve radyoi̇şaretleme veri̇mi̇ne sahi̇p radyofarmasöti̇kler ve bahsedi̇len radyofarmasöti̇kleri̇ i̇çeren teranosti̇k ki̇t
CN115212322B (zh) * 2022-06-01 2024-01-16 原子高科股份有限公司 一种用于放射性药物制备的冻干药盒及其制备方法
WO2025113628A1 (en) * 2023-11-30 2025-06-05 Full-Life Technologies Hk Limited Sstr receptor targeting radio compounds and uses thereof
EP4763231A1 (en) * 2024-12-20 2026-06-24 ITM Isotope Technologies Munich SE Para-aminohippuric acid as a stabilizer in radiopharmaceutical compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006176427A (ja) 2004-12-21 2006-07-06 Geno Membrane:Kk エストロン3硫酸トランスポーター活性の阻害剤
US20070025910A1 (en) 2005-07-29 2007-02-01 Norenberg Jeffrey P Anticancer therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070166774A1 (en) * 2006-01-17 2007-07-19 Groman Ernest V Functional immunoassay
CA2686933A1 (en) * 2007-04-06 2008-10-16 The Johns Hopkins University Methods and compositions for the treatment of cancer
JP5843338B2 (ja) 2011-08-05 2016-01-13 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 放射標識された前立腺特異的膜抗原阻害剤
SMT202300035T1 (it) 2013-03-15 2023-05-12 Cancer Targeted Tech Llc Metodi per preparare agenti di pet imaging marcati con 18f indirizzati al psma e metodi diagnostici con gli stessi
EP2862857A1 (en) 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
AU2014336638C1 (en) 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CA3060143A1 (en) 2017-05-24 2018-11-29 Itm Isotopen Technologien Munchen Ag Novel psma-binding agents and uses thereof
WO2020108753A1 (en) 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
WO2020224780A1 (en) * 2019-05-08 2020-11-12 ITM Isotopen Technologien München AG Para-aminohippuric acid (pah) as a renal protective substance

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006176427A (ja) 2004-12-21 2006-07-06 Geno Membrane:Kk エストロン3硫酸トランスポーター活性の阻害剤
US20070025910A1 (en) 2005-07-29 2007-02-01 Norenberg Jeffrey P Anticancer therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KWEKKEBOOM, Dik J et al.,Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors,Endocrine-Related Cancer,2010年,17,R53-R73,DOI:10.1677/ERC-09-0078

Also Published As

Publication number Publication date
WO2022096103A1 (en) 2022-05-12
DK4065176T3 (da) 2024-01-02
FI4065176T3 (fi) 2024-01-18
ZA202304769B (en) 2024-10-30
PL4065176T3 (pl) 2024-03-18
AU2021375728A9 (en) 2024-06-20
CN116981487A (zh) 2023-10-31
US20230414796A1 (en) 2023-12-28
CA3171718A1 (en) 2022-05-12
ES2967379T3 (es) 2024-04-30
AU2021375728A1 (en) 2023-06-15
HUE065304T2 (hu) 2024-05-28
EP4065176A1 (en) 2022-10-05
KR20230127212A (ko) 2023-08-31
EP4065176B1 (en) 2023-10-11
JP2023547689A (ja) 2023-11-13
WO2022096673A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
EP4065176B1 (en) Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
KR102934560B1 (ko) 신장 보호 물질로서의 파라-아미노히푸르산(pah)
US12605447B2 (en) Stable formulations for radionuclide complexes
RU2842991C1 (ru) Комбинация пара-аминогиппуровой кислоты (паг) и меченных радиоактивным изотопом комплексов, предназначенная для лечения рака
CA3171718C (en) Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
HK40078095B (en) Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
HK40078095A (en) Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
RU2804349C2 (ru) Парааминогиппуровая кислота (паг) как вещество для защиты почек
CA3203175A1 (en) Peptide receptor radionuclide therapy
HK40065088A (en) Para-aminohippuric acid (pah) as a renal protective substance
HK40065088B (en) Para-aminohippuric acid (pah) as a renal protective substance
WO2025218931A1 (en) Stable formulations comprising 225-actinium labeled complexes and methods for preparing the same
Chatal et al. Radiolabeled Antibodies for Cancer Imaging and Therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231109

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20231109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240521

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240716

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240730

R150 Certificate of patent or registration of utility model

Ref document number: 7531707

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150